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Background: Previous study showed that mitochondrial ND6 (mitND6) gene missense mutation resulted in NADH
dehydrogenase deficiency and was associated with tumor metastasis in several mouse tumor cell lines. In the
present study, we investigated the possible role of mitND6 gene nonsense and missense mutations in the
metastasis of human lung adenocarcinoma.
Methods: The presence of mitND6 gene mutations was screened by DNA sequencing of tumor tissues from 87
primary lung adenocarcinoma patients and the correlation of the mutations with the clinical features was analyzed.
In addition, we constructed cytoplasmic hybrid cells with denucleared primary lung adenocarcinoma cell as the
mitochondria donor and mitochondria depleted lung adenocarcinoma A549 cell as the nuclear donor. Using these
cells, we studied the effects of mitND6 gene nonsense and missense mutations on cell migration and invasion
through wounding healing and matrigel-coated transwell assay. The effects of mitND6 gene mutations on NADH
dehydrogenase activity and ROS production were analyzed by spectrophotometry and flow cytometry.
Results: mitND6 gene nonsense and missense mutations were detected in 11 of 87 lung adenocarcinoma
specimens and was correlated with the clinical features including age, pathological grade, tumor stage, lymph node
metastasis and survival rate. Moreover, A549 cell containing mitND6 gene nonsense and missense mutation
exhibited significantly lower activity of NADH dehydrogenase, higher level of ROS, higher capacity of cell migration
and invasion, and higher pAKT and pERK1/ERK2 expression level than cells with the wild type mitND6 gene. In
addition, NADH dehydrogenase inhibitor rotenone was found to significantly promote the migration and invasion
of A549 cells.
Conclusions: Our data suggest that mitND6 gene nonsense and missense mutation might promote cell migration
and invasion in lung adenocarcinoma, probably by NADH dehydrogenase deficiency induced over-production of
ROS.
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Lung cancer is one of the most common malignant tu-
mors in the world [1,2]. According to the etiologic and
pathologic characteristics, lung cancer could be divided
into two main forms, small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC) [3]. The incidence of* Correspondence: huangsd@smmu.edu.cn; zengzhiyong623@sina.com
†Equal contributors
1Department of Cardiothoracic Surgery, Changhai Hospital, Shanghai, P R China
4Department of Cardiothoracic Surgery, Fuzhou General Hospital of Nanjing
Command, PLA, Nanjing, China
Full list of author information is available at the end of the article
© 2015 Yuan et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.lung adenocarcinoma, a subtype of NSCLC, is by far the
most prevalent lung cancer in China [2,4]. Although novel
surgical treatment can prolong the survival time of the pa-
tients, the long-term survival rate of lung adenocarcinoma
after surgery remains low [1,2]. Molecular prognostic fac-
tors of lung adenocarcinoma such as nuclear DNA muta-
tions [5,6] have been investigated extensively in clinical
samples. However, whether mitochondrial DNA (mtDNA)
alteration is associated with tumor properties has not been
explored vigorously.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gated cylindrical particles originated in ancestral eukaryotic
cells through endosymbiosis of free living bacteria capable
of metabolizing oxygen [7-9]. It is well known that the core
functions of mitochondria include oxidative phosphoryl-
ation, amino acid metabolism, fatty acid oxidation, and ion
homeostasis [7-9]. In recent years, mounting data suggest
that mitochondria are involved in crucial cell properties
such as proliferation, differentiation and apoptosis [10,11].
Most mammalian cells contain 103 - 104 copies of mtDNA
and the mutation rate of mtDNA is much higher than that
of nuclear DNA [7,8]. Mitochondrial dysfunction as a result
of mtDNA mutation is increasingly recognized as an im-
portant cause of human disease [12]. MtDNA mutations
have been identified in various types of tumors including
lung adenocarcinoma [13].
MitND6 gene encodes ND6 subunit, which is one of
the 40 subunits of the NADH dehydrogenase (also
known as complex I), in mammalian cells [14]. In the
past ten years, a variety of point mutations of ND6 gene
were showed to affect NADH dehydrogenase activity
[15-18] leading to NADH dehydrogenase deficiency, and
were associated with maternally inherited diseases such
as Leber’s hereditary optic neuropathy (LHON) [15,16]
and mitochondrial encephalomyopathy with lactic acid-
osis and stroke-like episodes (MELAS) [17,18]. Using
a cytoplasmic hybrid technology with several tumor
cell lines, Ishikawa et al. [19] reported that ND6 mis-
sense mutation contribute to tumor cell metastasis in
mouse fibrosarcoma, lung carcinoma and colon can-
cer. However, the biological role of mitND6 gene mu-
tation in human lung adenocarcinoma cells has not
been documented.
Here we set out to evaluate the role of mitND6 gene
nonsense and missense mutation in human lung adeno-
carcinoma by clinical investigation and cellular experi-
ments. Clinical investigation showed that mitND6 gene
nonsense and missense mutation in lung adenocarcin-
oma cells was closely correlated with poor differenti-
ation, advanced stage, lymph node metastasis of the
tumor, and survival rate. With cytoplasmic hybrid cell
(nuclear removed primary lung adenocarcinoma cell as
mitochondria donor and mtDNA depleted A549 cell as
nuclear donor), we further demonstrate that cells with
mitND6 gene nonsense and missense mutation pro-
duced more reactive oxygen species (ROS) and exhibited
higher capacities of migration and invasion. Our results
suggest that mitochondrial ND6 gene nonsense and mis-
sense mutation in lung generation.
Methods
Lung adenocarcinoma specimens
A total of 87 primary lung adenocarcinoma patients that
underwent pulmonectomy were enrolled in this study.Tumor specimens and paired normal lung tissue specimens
taken from a site distant from the cancerous lesion were
obtained from the consenting patients, as approved by the
Medical Ethics Committee of Changhai Hospital and
Fuzhou General Hospital and all patients gave written con-
sent for use of tissue specimens. None of the patients re-
ceived radiotherapy or chemotherapy before surgery.
Clinical and pathological data including age, gender, patho-
logical grading, tumor stage and lymph node metastasis
were acquired from the medical records.
Cell culture
Human lung adenocarcinoma cell line A549 was pur-
chased from the Shanghai Institute of Biochemistry and
Cell Biology (Shanghai, China). Cells were maintained
in RPMI1640 (Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen), 100 U/mL penicillin and
100 μg/mL streptomycin, within a humidified atmos-
phere containing 5% CO2 at 37°C.
Lung adenocarcinoma samples were mechanically dis-
sociated and then digested in the medium containing
150 μg/mL Collagenase Type IV, 2 μg/mL DNase type I
and 10 μg/mL hyaluronidase type V (Sigma) for 2 hr at
37°C. The resulting cell suspension was filtered through
a 38-μm nylon mesh and single cells were harvested and
subsequently seed in 25 cm2 flasks. At confluency, cells
were subcultured following detachment by exposure to
0.25% trypsin for 2 min at 37°C. Cells were resuspended
in fresh RPMI 1640 medium with 10% fetal bovine
serum, within a humidified atmosphere containing 5%
CO2 at 37°C.
Sequencing of the Mitochondrial ND6 gene
The total cellular DNA of tissue samples were extracted
using QIAamp genomic DNA kits (Qiagen). The DNA
sample was kept at −20°C until use. The mitochondrial
ND6 gene was PCR amplified (sence: ggcataattaaactt-
tacttc; anti sence: catatcattggtcgtggttgtag) from the ex-
tracted DNA and then subjected to direct sequencing.
The PCR conditions were set at 94°C for 2 minutes
followed by 30 cycles of amplification at 94°C for 15 sec-
onds, 58°C for 15 seconds, and 68°C for 40 seconds, and
the final extension at 68°C for 6 minutes. PCR products
were subject to electrophoresis on a 1.5% agarose gel to
separate the DNA bands and visualized by ultraviolet
light illumination after ethidium bromide staining. The
DNA band of interest was then cut out of the gel and
subject to direct sequencing. The results were compared
in pairs with reference to the human mitochondrial gen-
ome database (http://www.mitomap.org/MITOMAP).
Construction of cytoplasmic hybrid
Cytoplasmic hybrids were constructed as previously
described [19]. Briefly, A549 cell subline without
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structed by 100 ng/mL ethidium bromide (EB) treat-
ing. Complete depletion of mtDNA was confirmed by
PCR analysis. Cultured cells from primary lung adeno-
carcinoma (with and without ND6 gene mutations as
mtDNA donor) were prepared by their pretreatment
with cytochalasin B (10 μg/mL) at 37°C for 20 min
and centrifugation at 9,000 × g at 37°C for 10 min. Re-
sultant cytoplasts were fused with ρ0 cells by poly-
ethylene glycol.
NADH dehydrogenase activity analysis
Cells in log-phase growth were harvested, and the mito-
chondrial NADH dehydrogenase activity was detected
with NADH Assay Kit (Abcam). Briefly, NADH and
cytochrome c (oxidized form) were used as substrates
for estimation of NADH dehydrogenase activity, and the
reduction of cytochrome c was monitored at 550 nm.
ROS production analysis
ROS generation was detected with mitochondrial super-
oxide indicator MitoSOX-RED (Invitrogen). Cells were
incubated with 5 μM MitoSOX-RED for 10 min at 37°C
in serum-free DMEM, washed twice with phosphate-
buffered saline (PBS), and then immediately analyzed
with a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA, USA). Those cells incubated with
MitoSOX-RED and exhibited red fluorescence were de-
termined as ROS positive cells.
Wound healing assay
Lung adenocarcinoma cells were seeded on 6-well plates
at a density of 5 × 105 cells/well. After the cells reached
sub-confluence, the mono-layer cells were wounded by
scraping off the cells and then grown in medium for
72 hr. The migrated distance of cells was monitored and
imaged under a microscope. The distances of cell migra-
tion were calculated by subtracting the distance between
the lesion edges at 48 hr from the distance measured at
0 hr. The relative migrating distance of cells is measured
by the distance of cell migration/the distance measured
at 0 hr.
Transwell assay
Cell migration and invasion were determined using a
transwell (Costar) with a pore size of 0.8 μm. 5 × 103
cells were seeded in serum-free medium in the upper
chamber (normal chamber for migration assay and
matrigel-coated chamber for invasion assay). The lower
chamber was filled with medium containing 10% FBS.
After incubating for 8 hr at 37°C, cells in the upper
chamber were carefully removed with a cotton swab and
the cells that had traversed to reverse face of themembrane were fixed in methanol, stained with Giemsa,
and counted.Statistical analysis
Statistical significance was tested using SPSS15.0 soft-
ware. For comparison of clinical features (except for
aging) between patients with and without ND6 gene mu-
tations, chi-square test was performed. The average age
between the patients with and without mitND6 gene
mutations was compared with Cochran & Cox t’ test.
Other data are presented as mean ± SEM, using student
t tests for 2-group comparison, and ANOVA for multi-
groups comparison with Bonferroni’s post-test. A P value
less than 0.05 is considered as statistically significant.Results
MitND6 gene nonsense and missense mutations are
correlated with age, pathological grade, tumor stage and
lymph node metastasis in lung adenocarcinoma
specimens
To determine the mitND6 gene mutations in lung
adenocarcinoma specimens, we compared each of the
mitND6 gene sequences of 87 patients to the Cambridge
Reference Sequence. A total of 26 mitND6 gene mu-
tations existed in 24 lung adenocarcinoma specimens
(22 samples with one mitND6 gene mutation and 2
samples with two mitND6 gene mutations). As shown
in Figure 1A-K, 8 mitND6 gene mutations were mis-
sense mutations that results in amino acid change of
ND6 protein, 3 were nonsense mutations that results
in premature termination of the translation of ND6
protein, and the other mutations were samesense mu-
tations that render the ND6 protein sequence unaltered.
In addition, the average age of the patients with mitND6
gene mutations was significantly higher than those with-
out mitND6 gene mutations (Figure 1L). As shown in
Table 1, mutations were more common in patients over
60 years of age, but there was no significant gender differ-
ence in incidence of mitND6 mutations. We further ana-
lyzed the relationship of mitND6 gene mutation with the
clinical features including pathological grade, tumor stage
and lymph node metastasis. It was found that missense
and nonsense, but not samesense, mitND6 gene muta-
tions were significantly correlated with the pathological
grade, tumor stage and lymph node metastasis (Table 1).
Moreover, ND6 gene missense and nonsense mutations
were associated with shorter survival rate, whereas sur-
vival rate of patients with ND6 gene samesense mutations
was not significantly different from those without ND6
gene mutations (Figure 1M). These results suggest that
the mitND6 gene nonsense and missense mutation
Figure 1 Mitochondrial ND6 gene nonsense and missense mutations in lung adenocarcinoma patients. (A-K) DNA sequencing electropherograms
showing point mutations of mitochondrial ND6 gene lead to the amino acid changes of the protein in 11 cases. (A-H) represent missense
mutation and (I-J) represent nonsense mutation. (L) The average age of the patients with or without mitND6 gene mutation. Each dot
represents the age of a patient (n = 24 for patients with mitND6 gene mutation, n = 63 for patients without mitND6 gene mutation) with
the line indicating the mean level; *, P < 0.05. (M) The survival rate of the patients with or without mitND6 gene mutation. n = 11 for
patients with missense and nonsense mitND6 gene mutation, n = 13 for patients with samesense mitND6 gene mutation, n = 63 for patients
without mitND6 gene mutation.
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lung adenocarcinoma.
MitND6 gene nonsense and missense mutations promote
migration and invasion of lung adenocarcinoma cell line
To study the effect of mitND6 gene nonsense and mis-
sense mutation on cell migration and invasion, we con-
structed A549 sublines expressing mitND6 gene with
missense and nonsense mutations by cytoplasmic hybridtechnology [19]. Hybrid A549 cells containing normal
mitochondrial, as well as normal A549 cells treated with
rotenone, were used as controls.
Through wound healing assay, we found that the
migrating distance of cells was significantly longer in
cells with mitND6 gene nonsense and missense muta-
tions and in cells treated with rotenone as compared
to those with the wild type mitND6 gene (Figure 2A).
Further, the mean migrating distance of cells with
Table 1 Relationship between mitochondrial ND6 gene mutation and clinical features of lung adenocarcinoma
Clinical features Lung adenocarcinoma samples







Total 11 13 63
Age (year)
<60 3/11 5/13 41/63 7.423 0.024
≥60 8/11 8/13 22/63
Gender
Male 7/11 9/13 43/63 0.106 0.949
Female 4/11 4/13 20/63
Pathological grading
Well 1/11 4/13 25/63 11.993 0.017
Moderately 4/11 7/13 30/63
Poorly 6/11c 2/13 8/63
Tumor stage
T1/T2 2/11 8/13 37/63 6.547 0.038
T3/T4 9/11 5/13 26/63
Lymph node metastasis
Negative 2/11 9/13 38/63 7.794 0.020
Positive 9/11 4/13 25/63
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with rotenone was similar and was significantly longer
than cells with mitND6 gene missense mutation
(Figure 2B).
In matrigel-coated transwell assay, the percentages of
cells invaded through the matrigel was significantly
higher in cells with mitND6 gene missense mutation
than cells with normal mitND6 gene, and was furtherFigure 2 Mitochondrial ND6 gene nonsense and missense mutation prom
images of different groups of A549 cells taken immediately (0 hr) and 72 h
relative migration distance of cells. Bars = 100 μm. Data represent mean ± Shigher in cells with mitND6 gene nonsense mutation
and in cells treated with rotenone. Cell invasion was
not significantly different between mitND6 nonsense
mutation group and rotenone-treated group (Figure 3).
These results suggest that nonsense and missense mu-
tation of mitND6 gene, like inhibitor of NADH dehydro-
genase, might promote migration and invasion of lung
adenocarcinoma cells.otes the migration of lung adenocarcinoma cells. (A) Representative
r after lesion in the wound healing assay. (B) Histogram showing the
EM from 4 independent experiments; **, P < 0.01.
Figure 3 Mitochondrial ND6 gene nonsense and missense mutation promotes the invasion of lung adenocarcinoma cells. (A) Representative
photographs showing invasion of different groups of A549 cells in the transwell assay. The invaded cells were stained with crystal violet.
(B) Histogram showed the percentage of invasive cells. Bars = 50 μm. Data represent mean ± SEM from 4 independent experiments; **, P < 0.01.
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the activity of NADH dehydrogenase, increase production
of ROS, and increases the activity of AKT and ERK/MAPK
in lung adenocarcinoma cell line
Since ND6 is a subunit of the NADH dehydrogenase, we
detected the effect of mitND6 gene nonsense and mis-
sense mutation on the activity of NADH dehydrogenase
in lung adenocarcinoma cells. As shown in Figure 4,
NADH dehydrogenase activity was reduced in A549 cells
with mitND6 gene missense mutation (p < 0.05 vs. cells
with normal mitND6 gene), and further reduced in cells
with mitND6 gene nonsense mutation and in cells
treated with rotenone (p < 0.01 and p < 0.05, respect-
ively, vs. cells with normal mitochondrial ND6 gene).
In addition, NADH dehydrogenase activity was not sig-
nificantly different between mitND6 nonsense mutation
and rotenone-treated cell groups. Hence, mitND6 gene
nonsense and missense mutation resulted in reduced
NADH dehydrogenase activity in lung adenocarcinoma
cells.
To study the role of mitochondrial ND6 gene non-
sense and missense mutation in the regulation of cellFigure 4 MitND6 gene nonsense and missense mutations inhibit the ac
by spectrophotometry. The histogram illustrates reduced NADH dehydro
mitND6 gene and cells treated with rotenone compared to A549 cells w
4 independent experiments; **, P < 0.01.migration and invasion, we further investigated the
cellular ROS level, since it was reported that defective
activity of NADH dehydrogenase could induce the in-
crease of ROS [7-9] and the level of ROS is relevant
to tumor cell migration, invasion and metastasis [11,19].
As shown in Figure 5A, the cellular ROS level was signifi-
cantly higher in A549 cells with mitochondrial ND6 gene
nonsense and missense mutations and cells treated with
rotenone as compared to those with normal mitochon-
drial ND6 gene. Further, cells with mitochondrial ND6
gene nonsense mutation and cells treated with rotenone
showed significantly higher cellular ROS level than cells
with mitochondrial ND6 gene missense mutation, while
there was no significantly difference between the last 2
groups (Figure 5B). These results suggest that the mito-
chondrial ND6 gene nonsense and missense mutation in-
crease production of ROS in lung adenocarcinoma cells.
ROS was reported to regulate tumor cell metastasis
through AKT and ERK/MAPK signal pathway [20,21]. In
the present study, our western blot results showed that
cells containing mitND6 gene nonsense and missense
mutation increased the expression level of phosphatetivity of NADH dehydrogenase. NADH dehydrogenase were analyzed
genase activity in cells with nonsense and missense mutations of
ith the wild type mND6 (normal). Data represent mean ± SEM from
Figure 5 Mitochondrial ND6 gene nonsense and missense mutation over-produces the ROS. ROS level was analyzed by flow cytometry.
(A) Representative flow cytometry graphs of A549 cells with the wild type mND6 (normal), cells with missense mutation and nonsense
mutations of mitND6 gene and cells treated with rotenone. Histogram represented the ROS level in cells. (B) Histogram showed the relative
ROS level of cells. Data represent mean ± SEM from 4 independent experiments; **, P < 0.01.
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fect on total AKT and ERK1/ERK2 (Figure 6A and B).
These results suggest that the mitochondrial ND6 gene
nonsense and missense mutation increases the activity
of AKT and ERK/MAPK in lung adenocarcinoma cell
line.Discussion
The major finding of the present study is that nonsense
and missense mutations of mitND6 gene are correlated
with the clinical features of lung adenocarcinoma and
that in adenocarcinoma cell lines (A549 cells) such mu-
tations lead to reduced NADH dehydrogenase activity,
increased ROS production and concomitantly promote
cell migration and invasion.
As the only extranuclear source of DNA in animal
cells, mitochondrial genome has unique characteristics
different from nuclear genomic DNA [7-9]. MtDNA is
not protected by histones, lacks nucleotide excision re-
pair is located in an environment with high levels of po-
tentially damaging ROS [22,23], and hence may be more
prone to mutations than nuclear DNA. Consistently, it
was reported that the rate of human mtDNA mutation
was approximately 17 times greater than that of nuclear
DNA [24]. mtDNA mutations have been detected in dif-
ferent types of tumors including lung adenocarcinoma.
Ishigawa et al. have shown that mtDNA missense muta-
tions might promote cell invasion and metastasis in
several mice tumor cell lines [19]. However, there still is
a lack of investigation into the relationship between
mitochondrial gene mutations and the clinical features
of tumors.In the present study, point mutations of mitND6 genes
were detected in 27.5% lung adenocarcinoma samples with
45.8% of the mutations being nonsense and missense muta-
tions that result in amino acid changes of the protein. Im-
portantly, nonsense and missense mutations of mitND6
were associated with poor differentiation grading, advanced
tumor stage, lymph node metastasis and shorter survival
rate, suggesting that mitND6 gene mutation may play an
important role in regulating the progression and metastasis
of lung adenocarcinomas. However, whether the status of
mitND6 mutations is an independent factor predicting me-
tastasis in lung cancer warrants further analysis with more
patients’ samples. In addition, we found that mitND6 gene
mutations were more common in lung adenocarcinoma pa-
tients over 60 years of age, and the average age was signifi-
cantly higher in the patients with mitND6 gene mutations
as compared to those without mitND6 gene mutations. It
was reported that cells accumulate somatic mutations of
mitochondrial DNA as part of normal ageing. These data
are consistent with the previous reports that mtDNA muta-
tions are accumulated during aging process [25,26].
Tumor metastasis is the major cause of low survival
rate of lung adenocarcinoma patients [27,28]. Previous
studies showed that the cybrid cells containing the
missense mutant mitND6 gene derived from the highly
metastatic mouse tumor cell lines conferred higher meta-
static potential, regardless of the nuclear background
[19]. Consistently, here we demonstrated that mitND6
gene nonsense and missense mutation significantly pro-
mote the migration and invasion of human lung ade-
nocarcinoma cell line A549. In addition, cells containing
mitND6 nonsense mutation showed significantly higher
migrate and invasive capacity than cells containing
Figure 6 Mitochondrial ND6 gene nonsense and missense mutation increases the activity of AKT and ERK/MAPK. AKT and ERK1/ERK2
expression level was determined by western blot. (A) Representative graphs of total and phosphate AKT and ERK1/ERK2 expression of A549
cells with the wild type mND6 (normal), cells with missense mutation and nonsense mutations of mitND6 gene and cells treated with
rotenone. (B) Histogram showed the relative total and phosphate AKT and ERK1/ERK2 expression level of cells Data represent mean ± SEM
from 4 independent experiments; *, P < 0.05; **, P < 0.01.
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clinical data indicated that the mitND6 gene nonsense
and missense mutation was significantly correlated
with lymph node metastasis of lung adenocarcinoma.
These results suggest that mitochondrial ND6 gene
nonsense and missense mutation may contribute to
the metastasis of lung adenocarcinoma.
ROS could function as signaling molecule to stimulate
tumor cell proliferation, promote genetic instability, and
contribute to carcinogenesis by affecting the expression
and activity of certain redox sensitive molecules. It is
well known that mitochondria is the major site of ROS
generation occurring mainly at NADH dehydrogenase of
the respiratory chain [7,9]. Recently, Ishikawa et al. re-
ported that mitND6 gene missense mutation induced
NADH dehydrogenase defects and in turn increased
ROS production in some mice tumor cell lines [19].However, the effect of mitND6 gene nonsense and mis-
sense mutation on the ROS production in human lung
adenocarcinoma cells has not been identified before. In
the present study, we found that mitND6 gene nonsense
and missense mutation resulted in inhibition of NADH
dehydrogenase activity and significantly higher levels of
ROS in A549 cells. In addition, cells containing mitND6
nonsense mutation exhibited significantly lower activity
of NADH dehydrogenase and significantly higher level of
ROS than cells containing mitDN6 missense mutation,
and showed no significant differences to those treated
with rotenone (an inhibitor of NADH dehydrogenase). It
was reported that treated cancer cells with diphenyliodo-
nium, a specific inhibitor of ROS generation, could reverse
the promotion of migration and invasion by ROS, suggest-
ing that ROS plays role in the regulation of cell migration
and invasion in cancer cells [20]. Combined with the
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tion could inhibit of NADH dehydrogenase activity and
increase the level of ROS in A549 cells, we suggest that
mitochondrial ND6 gene nonsense and missense muta-
tions may induce ROS over-production by reducing the
activity of NADH dehydrogenase and further regulate cell
migration and invasion in lung adenocarcinoma cells.
It was reported that increased generation of ROS
could promote the cell invasion and tumor metastasis in
some types of malignances including lung adenocarcin-
oma [29]. Consistent with the previous findings in hu-
man breast cancer [30], we found that rotenone caused
dramatic increase in ROS production and concomitant
increases in migration and invasion of A549 cells, sug-
gesting that dysfunction of NADH dehydrogenase may
enhance the metastatic potential of lung adenocarcin-
oma cells. Importantly, mitND6 gene nonsense and
missense mutation resulted in inhibition of NADH de-
hydrogenase activity, significantly higher levels of ROS,
and increasing the capacities of migrating and invasion
in A549 cells. ROS have been shown to play a role in the
AKT and ERK/MAPK activation, which plays essential
roles in tumor cells, and activation of these kinases may
increase the capacity of tumor cell migration, invasion
and metastasis [20,21]. Our results show that mitND6
gene nonsense and missense mutation could increase
the expression level of phosphate AKT and ERK1/ERK2,
but had no effect on total AKT and ERK1/ERK2. Based
on these findings, we propose that mitochondrial ND6
gene nonsense and missense mutation may contribute to
the metastasis of lung adenocarcinoma by reducing the
activity of NADH dehydrogenase and in turn the over-
production of ROS probably through AKT and ERK1/
ERK2 signal pathway.
Conclusions
In summary, we show here high incidence of nonsense
and missense point mutations of mitND6 gene in lung
adenocarcinoma, especially in patients over 60 years of
age. Such mutations were correlated with the patho-
logical grade, stage and lymph node metastasis of tumors.
In lung adenocarcinoma cell line (A549), nonsense and
missense mitND6 gene mutations resulted in significant
decrease in NADH dehydrogenase activity, increases in
ROS production and promoted cell migration and inva-
sion. These findings suggest that mitND6 gene nonsense
and missense mutations may contribute to the metastasis
of human lung adenocarcinoma.
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